Comme l’a annoncé la direction, Sanofi (FR0000120578) est en passe de racheter Bioverativ pour 11,6 Mds$ (9,5 Mds€). Ce laboratoire américain, spécialisé sur l’hémophilie et les autres troubles hématologiques graves, réalise environ 1 Mds$ de chiffre d’affaires, notamment par le biais de ses produits phares, l’Eloctate et l’Alprolix.
Thank you for signing up. Your address is already stored in our system - of course you will continue to receive the newsletter.
If you have requested a special report from us, you will receive it shortly by email.
However, we do not want to fail to take this opportunity to draw your attention to our other free newsletters . As part of the world\'s largest network of stock market information service providers for private investors, we work with numerous top experts .